Yes. Rejuvenate is a compounded prescription topical medication containing tretinoin, a teratogenic retinoid, which requires a valid prescription from a licensed healthcare provider. A telehealth consultation and medical intake are required before dispensing to confirm suitability, review contraindications, and counsel patients on the mandatory sun protection requirements for pigmentation therapy.

The most common side effects are tretinoin-related during the initial 2 to 4 week adjustment period: redness, peeling, or dryness as epidermal cell turnover accelerates. Niacinamide's barrier-protective properties meaningfully reduce this adjustment burden compared to tretinoin used alone. Increased UV photosensitivity is expected and managed by mandatory daily SPF, critical in pigmentation therapy, as UV exposure re-induces the melanin cascade that Rejuvenate is working to interrupt. Tranexamic acid rarely causes mild local irritation in sensitive skin. Contact dermatitis may occur in patients with hypersensitivity to any component.

Rejuvenate is contraindicated during pregnancy, tretinoin is teratogenic, and reliable contraception is required throughout treatment. It is not appropriate during breastfeeding. Patients with known retinoid sensitivity or allergy, documented hypersensitivity to tranexamic acid or niacinamide, or active inflammatory skin conditions (eczema, sunburn, broken skin) should not use this product without specific provider guidance. Patients with darker skin tones (Fitzpatrick III-VI) should begin with gradual every-other-night application due to elevated post-inflammatory hyperpigmentation risk during the adjustment period.

Other topical retinoids must not be combined in the same area, as this dramatically increases irritation without benefit. Benzoyl peroxide inactivates tretinoin on direct contact: do not apply simultaneously. AHAs and BHAs applied concurrently increase barrier disruption risk. Photosensitizing medications (certain antibiotics, diuretics, antifungals) further elevate UV sensitivity during tretinoin therapy, strict daily SPF is essential. Patients on systemic tranexamic acid for any indication should inform their provider. Hormonal contraceptives and menopausal HRT are primary melasma drivers and require ongoing rigorous sun protection even during Rejuvenate therapy.

Patients with significant photosensitivity disorders require individualized assessment before initiating retinoid therapy. Those with active inflammatory skin conditions should not begin treatment until skin is stable. Patients on oral retinoids (isotretinoin) must not use topical tretinoin concurrently. Any pre-existing pigmentation condition that has been evaluated by a dermatologist should be disclosed before starting, to ensure the correct diagnosis and treatment approach. Your provider will review your complete medical and skin history before prescribing.